6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A look at the biological mechanisms researchers believe drive NAFLD/MASLD progression, including lipid overload, mitochondrial dysfunction, the gut-liver axis, and genetic risk, with an honest account of what is established versus still under investigation.
NAFLD affects roughly 38% of adults worldwide under the newer MASLD criteria. This evidence-based overview covers global prevalence data, regional variation, risk factor trends, and what the 2023 nomenclature change means for clinicians and patients.
A clinical history of NAFLD and MASLD treatment from the 1980s to today, covering lifestyle interventions, vitamin E, pioglitazone, and the first FDA-approved therapy resmetirom, with primary-source citations throughout.
How NAFLD and MASLD differ between children and adults in histology, risk factors, diagnosis, and treatment. Evidence-based guide with primary citations.
A comprehensive clinical review of racial and ethnic disparities in NAFLD / MASLD prevalence, severity, genetics, and treatment access, with primary-source citations and guidance.
A detailed breakdown of the socioeconomic burden of NAFLD/MASLD: healthcare costs, lost productivity, disability, health disparities, and what updated MASLD criteria mean for population-level projections.